BSJ-05-037

Overview

BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB / GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma. (Pink: Itk ligand ( HY-11092 ); Blue: Cereblon ligand ( HY-103597 ); Black: linker ( HY-W036393 )).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Itk | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-185206
• CAS No.: 2756388-01-7
• Molecular Formula: C51H59N9O10S2
• Molecular Weight: 1022.20
• Purity: 99.83%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: ≥ 2.5 mg/mL (2.45 mM); Clear solution
• Availability: In-stock

Source

Original product source